Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis

Oncologist

Volumn 22, Issue 6, 2017, Pages 709-718

  Larkin, James ^a   Chmielowski, Bartosz ^b   Lao, Christopher D ^c   Hodi, F Stephen ^d   Sharfman, William ^e   Weber, Jeffrey ^f   Suijkerbuijk, Karijn P M ^g   Azevedo, Sergio ^h   Li, Hewei ⁱ   Reshef, Daniel ⁱ   Avila, Alexandre ⁱ   Reardon, David A ^d  

^a Royal Marsden   (United Kingdom)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h HOSPITAL MÃE DE DEUS   (Brazil)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

Case series; Encephalitis; Immune checkpoint inhibitors; Immune related adverse events; Melanoma; Neurologic adverse events

Indexed keywords

ACICLOVIR; AMPICILLIN; CEFEPIME; CEFTRIAXONE; CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; IPILIMUMAB; LACOSAMIDE; LEVETIRACETAM; LEVOFLOXACIN; MEROPENEM; METHYLPREDNISOLONE; MIDAZOLAM; NAPROXEN; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; PROTEIN; RITUXIMAB; TALIMOGENE LAHERPAREPVEC; TOPIRAMATE; VANCOMYCIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; APHASIA; ARACHNOIDITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE PARALYSIS; DEMYELINATION; DIZZINESS; DRUG DOSE INCREASE; DYSESTHESIA; ELECTROENCEPHALOGRAM; ENCEPHALITIS; FEMALE; FEVER; HEADACHE; HEMIPARESIS; HUMAN; LEUKOCYTOSIS; LUMBAR PUNCTURE; MALE; MELANOMA; MENINGITIS; MENINGOENCEPHALITIS; MICROANGIOPATHY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NERVE PARALYSIS; NEUROMUSCULAR DISEASE; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SENSORY NEUROPATHY; VERY ELDERLY; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; COMPLICATION; NEUROLOGIC DISEASE; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NERVOUS SYSTEM DISEASES;

EID: 85020881421     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0487     Document Type: Article

References (46)

1. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
2. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
3. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
4. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl JMed 2015;372:2521-2532.
5. Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, openlabel, phase 3 trial. Lancet Oncol 2015;16:375-384.
6. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-1982.
7. Boutros C, Tarhini A, Routier E et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13:473-486.
8. Lancaster E. Paraneoplastic disorders. Continuum (MinneapMinn) 2015;21:452-475.
9. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology 2013;2:e27384.
10. Steinman L. Conflicting consequences of immunity to cancer versus autoimmunity to neurons:Insights from paraneoplastic disease. Eur J Immunol 2014;44:3201-3205.
11. Topalian SL, Sharpe AH. Balance and imbalance in the immune system: Life on the edge. Immunity 2014;41:682-684.
12. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806-812.
13. YERVOY® (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company USA; 2015.
14. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo) 2013;2013:857519.
15. Liao B, Shroff S, Kamiya-Matsuoka C et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16:589-593.
16. Ibrahim RA, Berman DM, DePril V et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011;29(suppl):8583a.
17. OPDIVO® (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company USA; 2016.
18. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with nonsmall- cell lung cancer. Muscle Nerve 2016;54:507.
19. Shirai T, Sano T, Kamijo F et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016;46:86-88.
20. Mandel JJ, Olar A, Aldape KD et al. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014;344:229-231.
21. KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co. USA, Inc.; 2015.
22. Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, openlabel, phase 1b trial. Lancet Oncol 2016;17:717-726.
23. Zimmer L, Goldinger SM, Hofmann L et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-225.
24. Boyd K, Kalladka D, Overell J et al. Ipilimumab induced encephalitis: A case report. Immunome Res 2015;11:092.
25. Carl D, Grüllich C, Hering S et al. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: A case report. BMC Res Notes 2015;8:316.
26. Conry RM, Sullivan JC, Nabors LB 3rd. Ipilimumab- induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 2015;3:598-601.
27. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016;2016:pii:bcr2016215012.
28. Williams TJ, Benavides DR, Patrice KA et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928-933.
29. Maur M, Tomasello C, Frassoldati A et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012;30:e76-e78.
30. LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. J Oncol PharmPract 2017;23:71-74.
31. Khoja L, Maurice C, Chappell M et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016;4:175-178.
32. Tunkel AR, Glaser CA, Bloch KC et al. The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008;47:303-327.
33. Bloch KC, Glaser C. Diagnostic approaches for patients with suspected encephalitis. Curr Infect Dis Rep 2007;9:315-322.
34. Kazandjian D, Suzman DL, Blumenthal G et al. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. The Oncologist 2016;21:634-642.
35. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-2017.
36. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl JMed 2012;366:2443-2454.
37. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030.
38. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl JMed 2013;369:122-133.
39. Urba WJ, Martin-Algarra S, Callahan M et al. Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma. Paper presented at the AACR AnnualMeeting; April 18-22, 2015; Philadelphia, PA.
40. Weber JS, Gibney G, Sullivan RJ et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advancedmelanoma (CheckMate 064): An open-label, randomised, phase 2 trial. Lancet Oncol 2016;17:943-955.
41. Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558-1568.
42. Ascierto PA, Demidov LV, Garbe C et al. Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172). J Clin Oncol 2016;34(suppl):9526a.
43. Chapman PB, Sznol M, Lao C et al. Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). J Clin Oncol 2016;34(suppl):9525a.
44. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-830.
45. Bompaire F, Mateus C, Taillia H et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs 2012;30:2407-2410.
46. Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016;27:559-574.